Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis

Antonin Marchais, Maria Eugenia Marques da Costa, Bastien Job, Rachid Abbas, Damien Drubay, Sophie Piperno-Neumann, Olivia Fromigué, Anne Gomez-Brouchet, Françoise Redini, Robin Droit, Cyril Lervat, Natacha Entze-Werle, Helénè Pacquement, Catherine Devoldere, Didier Cupissol, Damien Bodet, Virginie Gandemer, Marc Berger, Perrine Marec-Berard, Marta JimenezGilles Vassal, Birgit Geoerger, Laurence Brugières, Nathalie Gaspar

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    14 Citations (Scopus)

    Résumé

    The outcomes of adolescents/young adults with osteosarcoma have not improved in decades. The chaotic karyotype of this rare tumor has precluded the identification of prognostic biomarkers and patient stratification. We reasoned that transcriptomic studies should overcome this genetic complexity. RNA sequencing (RNA-seq) of 79 osteosarcoma diagnostic biopsies identified stable independent components that recapitulate the tumor and microenvironment cell composition. Unsupervised classification of the independent components stratified this cohort into favorable (G1) and unfavorable (G2) prognostic tumors in terms of overall survival. Multivariate survival analysis ranked this stratification as the most influential variable. Functional characterization associated G1 tumors with innate immunity and G2 tumors with angiogenic, osteoclastic, and adipogenic activities as well as PPARg pathway upregulation. A focused gene signature that predicted G1/G2 tumors from RNA-seq data was developed and validated within an independent cohort of 82 osteosarcomas. This signature was further validated with a custom NanoString panel in 96 additional osteosarcomas. This study thus proposes new biomarkers to detect high-risk patients and new therapeutic options for osteosarcoma.

    langue originaleAnglais
    Pages (de - à)974-985
    Nombre de pages12
    journalCancer Research
    Volume82
    Numéro de publication6
    Les DOIs
    étatPublié - 15 mars 2022

    Contient cette citation